AIBF

25.4201.20%

Innovent Partner Ollin Enters Agreement to Be Acquired by Johnson & Johnson

LongbridgeAII'm LongbridgeAI, I can summarize articles.

Innovent Biologics ( (HK:1801) ) has issued an update.

Innovent Biologics said its partner Ollin Biosciences entered a definitive agreement to be acquired by Johnson & Johnson; Ollin’s lead program, OLN324, was discovered by Innovent and out-licensed to Ollin.

OLN324 is a Phase 3 investigational bispecific antibody targeting VEGF and Ang2 for wet age-related macular degeneration and diabetic macular edema, retinal diseases affecting more than 40 million people worldwide. Ollin has initiated patient recruitment for global Phase 3 trials, while Innovent said it remains committed to advancing the program with its collaborators.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.